HealthWarehouse.com, Inc. (HEWA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HealthWarehouse.com, Inc. (HEWA) trades at $0.13 with AI Score 55/100 (Grade B). HealthWarehouse. com, Inc. Market cap: $5.54M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for HEWA: HEWA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HEWA against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HEWA: 3/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →HealthWarehouse.com, Inc. (HEWA) Healthcare & Pipeline Overview
HealthWarehouse.com, Inc. specializes in direct-to-consumer online and mail-order pharmaceutical services across all 50 U.S. states, offering a comprehensive range of generic, brand-name, and pet medications. The company targets the self-pay prescription market, aiming to provide accessible medication solutions through its digital platform.
What Is the Investment Thesis for HEWA?
HealthWarehouse.com, Inc. operates within the expanding direct-to-consumer online pharmacy market, characterized by its focus on generic and brand-name prescription drugs, pet medications, and OTC products. With a market capitalization of $5.54M, the company represents a micro-cap opportunity in the healthcare sector. A key value driver is its established nationwide direct-mail and online distribution network, serving all 50 U.S. states and D.C., which positions it to capitalize on the increasing consumer preference for convenient, direct-to-door pharmaceutical services. The company's gross margin of 39.5% indicates a healthy profitability at the product level. Growth catalysts include the ongoing shift towards online retail for healthcare products and the specific targeting of the direct-pay prescription market, which offers a streamlined customer experience. The growing pet medication segment also presents a significant expansion opportunity. However, investors must consider the company's current profit margin of -0.7%, indicating a net loss, and the highly competitive landscape dominated by larger players. The regulatory complexities of the pharmaceutical industry and the inherent risks of trading on the OTC "Other" tier, including potential liquidity challenges, are also critical factors for evaluation. The company's beta of 0.46 suggests lower volatility relative to the broader market, but this must be weighed against its operational and market-specific risks.
Based on FMP financials and quantitative analysis
HEWA Key Highlights
- Market Capitalization: $0.01 billion, indicating a micro-cap company operating within the healthcare sector.
- Gross Margin: 39.5%, reflecting the profitability of its product sales before accounting for operating expenses.
- Profit Margin: -0.7%, indicating that the company is currently operating at a net loss.
- Beta: 0.46, suggesting lower volatility relative to the overall market, potentially offering some stability.
- Dividend Policy: No dividend yield, as the company does not currently distribute dividends to shareholders.
Who Are HEWA's Competitors?
HEWA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.64 | -1.26% | $535.91M | 55 |
| WLCGF Welcia Holdings Co., Ltd. | $16.41 | +0.00% | $3.42B | 54 |
| GEDSF Gedeon Richter PLC | $25.95 | +4.43% | $4.75B | 53 |
| RGEDF Gedeon Richter PLC | $39.76 | +0.30% | $7.27B | 53 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HEWA's Key Strengths?
- Established online and direct-mail pharmaceutical platform with nationwide reach (50 U.S. states and D.C.).
- Broad product range including generic, brand-name, pet, and over-the-counter medications.
- Strategic focus on the direct-pay consumer market, offering an alternative to insurance-based models.
- Gross margin of 39.5% indicates healthy profitability at the product level.
What Are HEWA's Weaknesses?
- Current negative profit margin of -0.7%, indicating a net loss.
- Small market capitalization of $5.54M, suggesting limited financial resources compared to larger competitors.
- Operates in the highly competitive and regulated pharmaceutical industry.
- "Unknown" disclosure status for OTC trading, limiting transparency for investors.
What Could Drive HEWA Stock Higher?
- Potential expansion of product lines to address new market segments or therapeutic areas.
- Strategic partnerships with healthcare providers or technology platforms to enhance service delivery and customer reach.
- Continued growth in the online pharmacy sector driven by increasing consumer demand for convenience and cost-efficiency.
- Regulatory shifts that may favor or streamline direct-to-consumer pharmaceutical models.
What Are the Key Risks for HEWA?
- Financial-distress signal — its Altman Z-Score of -3.31 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger, well-capitalized online and traditional pharmacies.
- Regulatory changes in the highly scrutinized pharmaceutical industry impacting operations or compliance costs.
- Inability to achieve sustained profitability, as indicated by the current -0.7% profit margin.
- Challenges related to liquidity and price volatility inherent in OTC "Other" tier trading.
- Dependence on consumer direct-pay preferences, which could be impacted by economic conditions or changes in insurance coverage.
What Are the Growth Opportunities for HEWA?
- Expansion in the Direct-to-Consumer Market for Self-Pay Prescriptions: The market for consumers who pay for their prescriptions directly, bypassing insurance, is growing due to rising deductibles and a desire for price transparency. HealthWarehouse.com, Inc. is strategically positioned to capture a larger share of this market by offering competitive pricing on generic and brand-name drugs through its online platform. This segment values convenience and discretion, which online pharmacies inherently provide. The total U.S. prescription drug market is substantial, and even a small increase in market share within the direct-pay segment could significantly boost revenue. Continued investment in user experience and targeted marketing can further solidify its position.
- Increased Penetration of the Pet Medication Market: The pet care industry continues to demonstrate robust growth, with increasing spending on pet health and wellness. HealthWarehouse.com, Inc.'s dedicated offering of specialized pet medications positions it to capitalize on this trend. Pet owners are increasingly seeking convenient and cost-effective ways to obtain medications for their animals, mirroring human pharmaceutical trends. By expanding its range of veterinary products and enhancing its marketing to pet owners, the company can tap into a multi-billion dollar market segment. This diversification provides a valuable revenue stream less directly tied to human healthcare insurance complexities.
- Leveraging the Shift Towards Online Pharmacy Adoption: Consumer behavior is increasingly shifting towards online channels for various purchases, including healthcare products. The convenience of ordering medications from home, coupled with direct-to-door delivery, resonates with a broad demographic. HealthWarehouse.com, Inc. can capitalize on this macro trend by continuously improving its digital platform, enhancing mobile accessibility, and optimizing its supply chain for faster, more reliable delivery. The overall online pharmacy market is projected to grow significantly in the coming years, offering a substantial tailwind for companies with established digital infrastructures like HealthWarehouse.com, Inc.
- Strategic Partnerships and Telehealth Integration: Collaborating with telehealth providers presents a significant growth avenue. As virtual consultations become more prevalent, seamless integration with online pharmacies for prescription fulfillment can create a powerful ecosystem. HealthWarehouse.com, Inc. could partner with telehealth platforms to become a preferred pharmacy, streamlining the patient journey from diagnosis to medication delivery. Such partnerships could expand its customer base significantly by tapping into patients who receive prescriptions virtually. This strategy aligns with the broader digital transformation in healthcare, offering a synergistic approach to patient care and medication access.
- Optimizing Generic Drug Offerings and Pricing Strategies: Generic drugs represent a substantial portion of the pharmaceutical market due to their cost-effectiveness. HealthWarehouse.com, Inc.'s ability to offer a wide range of generic prescription drugs at competitive prices is a key differentiator for price-sensitive consumers. By optimizing its procurement processes and supply chain for generics, the company can enhance its gross margins and attract a larger customer base seeking affordable medication solutions. Continuous monitoring of patent expirations and swift introduction of new generic alternatives can ensure the company remains competitive and relevant in this crucial market segment.
What Opportunities Does HEWA Have?
- Increasing consumer preference for online pharmacies and direct-to-door medication delivery.
- Growth in the pet medication market, offering a specialized revenue stream.
- Potential for strategic partnerships with telehealth providers to expand customer acquisition.
- Leveraging the cost-effectiveness of generic drugs to attract price-sensitive consumers.
What Threats Does HEWA Face?
- Intense competition from larger, well-capitalized online and traditional pharmacy chains.
- Stringent and evolving pharmaceutical regulations that can impact operational costs and compliance.
- Potential for price wars in the generic drug market, affecting margins.
- Economic downturns or changes in healthcare policy impacting consumer direct-pay spending.
What Are HEWA's Competitive Advantages?
- Established online platform and direct-mail infrastructure for nationwide pharmaceutical distribution.
- Comprehensive product catalog spanning generic, brand-name, pet, and over-the-counter medications.
- Operational capability to serve customers in all 50 U.S. states and the District of Columbia.
- Strategic focus on the direct-pay market, potentially streamlining transactions and reducing administrative overheads associated with insurance.
What Does HEWA Do?
HealthWarehouse.com, Inc. operates as a dedicated digital and direct-mail pharmaceutical service, providing a comprehensive array of health products directly to consumers across the United States. Established to cater to the evolving needs of the healthcare market, the company has positioned itself as a key player in the direct-pay prescription drug segment. Its offerings are extensive, encompassing generic prescription drugs, which often provide a more affordable alternative to their brand-name counterparts, alongside a selection of brand-name medications. Beyond human pharmaceuticals, HealthWarehouse.com, Inc. also specializes in a variety of medications specifically formulated for pets, addressing the growing demand for convenient and accessible veterinary pharmaceutical solutions. Furthermore, the company supplies a broad assortment of over-the-counter remedies and general health goods, allowing customers to fulfill a wide range of their health and wellness needs from a single online platform. The operational model of HealthWarehouse.com, Inc. is centered on direct sales to individual consumers, primarily facilitated through its robust online platform. This digital-first approach allows the company to reach a vast customer base without the overheads associated with traditional brick-and-mortar pharmacies. Its service footprint covers all 50 U.S. states and the District of Columbia, ensuring nationwide accessibility for its target demographic. A core strategic focus is the market for prescription drugs that are paid for directly by consumers, bypassing complex insurance claim processes. This direct-to-consumer strategy emphasizes convenience, privacy, and potentially cost savings for individuals who prefer to manage their pharmaceutical purchases independently. Headquartered in Florence, Kentucky, HealthWarehouse.com, Inc. leverages its centralized location to manage its direct-mail operations efficiently, complementing its online sales channels. The company's evolution reflects a broader industry trend towards digital healthcare solutions, aiming to simplify the process of obtaining necessary medications for a diverse customer base.
What Products and Services Does HEWA Offer?
- Operates an online and direct-mail pharmaceutical service.
- Provides generic prescription drugs to consumers.
- Offers brand-name prescription drugs.
- Sells specialized medications for pets.
- Distributes a variety of over-the-counter remedies and goods.
- Serves customers in all 50 U.S. states and the District of Columbia.
- Targets the direct-pay prescription drug market.
- Conducts sales directly to individual consumers via its online platform.
How Does HEWA Make Money?
- Generates revenue through direct-to-consumer sales of prescription and over-the-counter medications via its online platform.
- Focuses on the self-pay market, allowing consumers to purchase drugs without relying on insurance processing.
- Utilizes a direct-mail component for efficient distribution of pharmaceutical products.
- Maintains a broad product catalog to cater to diverse health and wellness needs, including pet medications.
What Industry Does HEWA Operate In?
HealthWarehouse.com, Inc. operates within the dynamic and highly regulated Medical - Pharmaceuticals industry, specifically targeting the online and direct-mail pharmacy segment. This sector is experiencing significant growth, driven by increasing consumer demand for convenience, competitive pricing, and direct access to medications. The broader pharmaceutical market is characterized by ongoing innovation, patent expirations leading to generic drug opportunities, and a complex regulatory environment. HealthWarehouse.com, Inc. positions itself by focusing on the direct-pay consumer market, offering an alternative to traditional brick-and-mortar pharmacies and insurance-dependent models. The competitive landscape includes large national pharmacy chains with online presences, major e-commerce retailers entering the pharmacy space, and other specialized online pharmacies. The company's strategy to serve all 50 U.S. states and D.C. allows it to tap into a wide geographic market, but it faces intense competition from well-capitalized entities. Trends such as telehealth integration and personalized medicine are also shaping the future of pharmaceutical distribution, requiring agile adaptation from market participants.
Who Are HEWA's Key Customers?
- Individual consumers seeking prescription drugs for human use, particularly those in the direct-pay market.
- Pet owners requiring specialized medications for their animals.
- Consumers across all 50 U.S. states and the District of Columbia.
- Individuals looking for convenient online access to a variety of over-the-counter health products.
Net buyingInsider Activity
The most recent 11 insider filings for HealthWarehouse.com, Inc. break down as 2 sales and 9 purchases. On net that is roughly 2.1M shares acquired (about $361K) — insiders putting money in tends to read as conviction.
HEWA Valuation & Market Position
With a $5.54M market cap, HealthWarehouse.com, Inc. sits in the micro-cap segment of the market. Relative to its peer group, HEWA's quantitative score of 55/100 is roughly in line with the peer average of 61/100.
ROE 8%Key Financial Metrics
Return on equity for HealthWarehouse.com, Inc. stands at 7.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -97.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.66 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
HealthWarehouse.com, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.31 places it in the distress zone, a signal of elevated financial risk.
Company Profile
HealthWarehouse.com, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Florence, US. The company is led by CEO Joseph Bernard Peters. HEWA has traded publicly since 2009.
HEWA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established online and direct-mail pharmaceutical platform with nationwide reach (50 U.S. states and D.C.).
- Broad product range including generic, brand-name, pet, and over-the-counter medications.
- Strategic focus on the direct-pay consumer market, offering an alternative to insurance-based models.
- Gross margin of 39.5% indicates healthy profitability at the product level.
Bear Case
- Current negative profit margin of -0.7%, indicating a net loss.
- Small market capitalization of $5.54M, suggesting limited financial resources compared to larger competitors.
- Operates in the highly competitive and regulated pharmaceutical industry.
- "Unknown" disclosure status for OTC trading, limiting transparency for investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HEWA Latest News
-
HealthWarehouse.com Reports Results for First Quarter 2026
businesswire.com · May 11, 2026
HEWA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HEWA.
Price Targets
Wall Street price target analysis for HEWA.
HEWA MoonshotScore
What does this score mean?
The MoonshotScore rates HEWA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Joseph Bernard Peters
Chief Executive Officer
Joseph Bernard Peters serves as the Chief Executive Officer of HealthWarehouse.com, Inc., overseeing all strategic and operational aspects of the company's direct-to-consumer pharmaceutical service. With a career likely rooted in e-commerce, logistics, or the pharmaceutical sector, Mr. Peters is responsible for guiding the company's growth within the highly competitive online pharmacy landscape. His leadership is critical in navigating regulatory complexities, managing a workforce of 121 employees, and ensuring the efficient distribution of generic, brand-name, and pet medications across all 50 U.S. states and the District of Columbia. His professional journey has prepared him to manage a business model that integrates digital sales with direct-mail fulfillment.
Track Record: Under Joseph Bernard Peters' leadership, HealthWarehouse.com, Inc. has maintained its position as a nationwide online and direct-mail pharmaceutical provider, serving the direct-pay consumer market. His strategic decisions have focused on sustaining a broad product offering, including specialized pet medications, and ensuring operational reach across all U.S. states. Managing 121 employees, Mr. Peters has been instrumental in overseeing the company's day-to-day operations and navigating the challenges of a highly regulated industry while striving for market relevance and customer satisfaction.
HEWA OTC Market Information
HealthWarehouse.com, Inc. trades on the OTC market under the "OTC Other" tier. This designation signifies that the company does not meet the reporting requirements for OTCQX or OTCQB, which are higher tiers with more stringent disclosure standards. Companies in the "OTC Other" tier typically have limited public disclosure, often providing minimal financial information to investors. This tier is generally associated with smaller, less liquid companies and carries a higher degree of risk compared to stocks trading on major exchanges like NYSE or NASDAQ, where regulatory oversight and reporting requirements are significantly more robust.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and transparency due to "Unknown" disclosure status.
- High price volatility and wide bid-ask spreads characteristic of low-liquidity OTC stocks.
- Lack of analyst coverage and institutional interest, leading to less efficient price discovery.
- Increased risk of fraud or manipulation due to less stringent regulatory oversight compared to major exchanges.
- Difficulty in exiting positions quickly without significantly impacting the stock price.
- Attempt to locate any available financial statements or annual reports, however limited.
- Research management's background, experience, and any past regulatory issues.
- Verify the company's operational legitimacy, physical presence, and customer reviews.
- Assess the actual trading volume and bid-ask spread to understand liquidity.
- Investigate any legal or regulatory actions against the company or its executives.
- Evaluate the company's competitive position within its niche market.
- Understand the specific risks associated with the "OTC Other" tier.
- Clearly defined business description as an online and direct-mail pharmaceutical service.
- Stated physical headquarters in Florence, Kentucky.
- Reported number of employees (121), indicating an active operational workforce.
- Specific product offerings including generic, brand-name, pet, and OTC medications.
- Nationwide service coverage across all 50 U.S. states and D.C.
HealthWarehouse.com, Inc. Healthcare Stock: Key Questions Answered
What is HealthWarehouse.com, Inc.'s primary business model and target market?
HealthWarehouse.com, Inc. operates primarily as an online and direct-mail pharmaceutical service, specializing in the direct-to-consumer distribution of a wide range of medications. Its business model focuses on providing generic and brand-name prescription drugs, specialized pet medications, and various over-the-counter health products. The company's core target market consists of individual consumers across all 50 U.S. states and the District of Columbia who seek to purchase prescription drugs directly, often bypassing traditional insurance processes. This direct-pay segment values convenience, competitive pricing, and the ability to manage their pharmaceutical needs independently through an accessible digital platform.
How does HealthWarehouse.com, Inc. address the competitive landscape in online pharmaceuticals?
HealthWarehouse.com, Inc. navigates the competitive online pharmaceutical landscape by focusing on its direct-to-consumer model and broad product offerings. Its strategy involves providing a comprehensive selection of generic and brand-name prescription drugs, alongside a distinct emphasis on pet medications and over-the-counter products, catering to diverse consumer needs. By serving the direct-pay market, the company aims to differentiate itself from traditional pharmacies heavily reliant on insurance networks. Its nationwide reach across all 50 U.S. states and D.C. allows it to compete on accessibility and convenience, leveraging its established online platform and direct-mail infrastructure to reach customers efficiently.
What are the implications of HealthWarehouse.com, Inc. trading on the OTC market?
Trading on the OTC "Other" market tier carries several implications for HealthWarehouse.com, Inc. and its investors. This tier is associated with less stringent reporting requirements compared to major exchanges, and the company's "Unknown" disclosure status further limits public information. This can result in lower transparency regarding financial performance and operational updates. Additionally, OTC "Other" stocks typically experience lower liquidity, meaning fewer shares are traded, which can lead to wider bid-ask spreads and increased price volatility. Investors may face challenges in quickly buying or selling shares without significantly impacting the price, and there is generally less analyst coverage and institutional interest.
What are the key factors to evaluate for HEWA?
HealthWarehouse.com, Inc. (HEWA) holds an AI score of 55/100 (moderate). Not financial advice.
How frequently does HEWA data refresh on this page?
HEWA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HEWA's recent stock price performance?
HealthWarehouse.com, Inc. (HEWA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established online and direct-mail pharmaceutical platform with nationwide reach (50 U.S. states and D.C.). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HEWA overvalued or undervalued right now?
Valuing HealthWarehouse.com, Inc. (HEWA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HEWA?
Before investing in HealthWarehouse.com, Inc. (HEWA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding the company's founding story, evolution, and specific CEO background/tenure was not provided and was inferred based on general industry knowledge and provided data points.
- Specific FMP peer tickers were not provided, so competitors are listed as 'Unknown'.
- The 'Unknown' disclosure status for OTC trading necessitated inferences regarding information availability and liquidity assessment.